Founding Platinum Sponsor

Wilson Sonsini Goodrich Rosati

Wilson Sonsini Goodrich & Rosati is the premier provider of legal services to technology, life sciences, and growth enterprises worldwide and has one of the largest life sciences practices in the United States. The firm has a 60-plus-year history of representing trailblazers in the life sciences industry, from the earliest innovators to those shaping the future of healthcare today. Our multidisciplinary team of attorneys, patent agents, and scientific advisors works closely with entrepreneurs, scientists, and investors who trust the firm’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships, and often act as outside general counsel with support from our cross-functional, global life sciences team. Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry.

www.wsgr.com

Supported By

Shanghai Center of Biomedicine Development

Established in 1994, Shanghai Center of Biomedicine Development (SCBD) is an second-class scientific research institution directly administrated by Science & Technology Commission of Shanghai Municipality (STCSM). The main functions include undertaking researches related to technological innovation and industrial development in the fields of life sciences and biomedicine in Shanghai, common technology R&D, project management and services, construction of sci-tech innovation bases, transformation of scientific and technological achievements, investment promotion and enterprise services, talent training, as well as management services for human genetic resources and laboratory animals.

www.biomed.org.cn

PR Partner

Hankang Capital

Founded in 2015, Hankang Capital is a specialized venture capital firm dedicated to the biotech industry. Headquartered in Shanghai with a strategic presence in Beijing and Hong Kong, we are positioned to bridge China’s R&D excellence with global innovation. Guided by our mission to “Empower Biomedical Innovation and Safeguard Human Health”, we partner with visionary entrepreneurs to provide end-to-end support across the entire drug development lifecycle, and our goal is to advance breakthrough therapeutics that address critical unmet medical needs across major therapeutic areas and diverse modalities on a global scale. To date, Hankang Capital has invested in over 50 high-potential companies, fostering industry leaders such as Akesobio, InnoCare, Keymed Biosciences, Abbisko, DualityBio, and Leads Biolabs. Our portfolio has built a consistent track record of successful IPOs on the HKEX and A-share markets, alongside extensive out-licensing and co-development partnerships with global MNCs. With multiple drug candidates having received regulatory approvals from the NMPA and FDA, Hankang remains committed to delivering lasting clinical value and investment impact.